Page last updated: 2024-12-09

1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea is an organic compound with a chemical formula C12H11ClN2S2. It is a thiourea derivative that contains both a chlorophenyl and a thiophene group.

**Why is it important for research?**

While specific research on this exact compound might be limited, thiourea derivatives in general are a class of compounds with significant research interest due to their diverse biological activities. Here's why 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea could be of interest to researchers:

* **Potential Anti-Cancer Activity:** Thiourea derivatives have been explored for their potential to inhibit cancer cell growth. The specific structure of this compound could potentially influence its interaction with specific cancer targets.
* **Antimicrobial Properties:** Some thioureas exhibit antimicrobial activity against bacteria and fungi. The combination of the chlorophenyl and thiophene groups might contribute to the compound's antimicrobial potential.
* **Enzyme Inhibition:** Thioureas can act as inhibitors of various enzymes, including those involved in metabolic pathways. This compound could potentially be explored for its ability to inhibit specific enzyme targets.
* **Ligand for Metal Complexes:** The sulfur atoms in the thiourea group can coordinate with metal ions, making this compound a potential ligand for the formation of metal complexes. Metal complexes have applications in areas like catalysis and medicinal chemistry.

**Important Note:** Without specific research on 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea, it is impossible to definitively say why it is important for research. It's essential to look for specific research publications or data related to this particular compound to understand its exact significance.

**To further explore this compound:**

* **Search scientific databases:** Use databases like PubMed, SciFinder, or Google Scholar to look for published research articles on 1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea or similar thiourea derivatives.
* **Contact research labs:** Reach out to research groups specializing in organic chemistry, medicinal chemistry, or related fields to inquire about their knowledge of this compound.

Cross-References

ID SourceID
PubMed CID2059105
CHEMBL ID1422275
CHEBI ID113099

Synonyms (15)

Synonym
smr000193493
MLS000571408
AK-968/40426856
n-(3-chlorophenyl)-n'-(2-thienylmethyl)thiourea
STK077054
1-(3-chlorophenyl)-3-(thiophen-2-ylmethyl)thiourea
CHEBI:113099
AKOS001636868
HMS2446N19
AB00100062-01
CHEMBL1422275
Q27193563
SR-01000465062-1
sr-01000465062
1-(3-chlorophenyl)-3-[(thiophen-2-yl)methyl]thiourea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.41250.100020.879379.4328AID588453
Smad3Homo sapiens (human)Potency3.54810.00527.809829.0929AID588855
PINK1Homo sapiens (human)Potency12.58932.818418.895944.6684AID624263
ParkinHomo sapiens (human)Potency12.58930.819914.830644.6684AID624263
IDH1Homo sapiens (human)Potency35.48130.005210.865235.4813AID686970
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.06820.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]